Venus Remedies secures GMP approval from UNICEF

Image
Last Updated : Mar 11 2025 | 8:11 AM IST

Venus Remedies announced that it has secured good manufacturing practices (GMP) approval from the United Nations Children's Fund (UNICEF) to supply Cephalosporin antibiotics for treating infections.

UNICEF, an esteemed agency of the United Nations, is recognized globally for its efforts in providing humanitarian aid and development support to children in need.

The companys manufacturing unit, located in Baddi, Himachal Pradesh, lndia has been approved to supply UNICEF with Cephalosporin antibiotics for treating infections.

The company's allegiance to maintaining the highest standards of manufacturing excellence, as evidenced by its compliance with WHO Technical Report Series 986, reinforces its position as a trusted partner in global healthcare supply chains, it added.

Saransh Chaudhary, president, Global Critical Care, Venus Remedies CEO, Venus Medicine Research Centre, said, The recognition from UNICEF, further validates our relentless pursuit of excellence in pharmaceutical manufacturing. The approval will further help us to make substantial contributions to global healthcare initiatives of UNICEF and positively influence communities worldwide."

Akshansh Chaudhary, executive director, Venus Remedies, emphasized the significance of approval, remarking, "This endorsement from UNICEF aligns with our mission to enhance access to quality healthcare globally. We look forward to leveraging this opportunity to extend our reach and serve those in need.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed-dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.

The companys consolidated net profit zoomed 108.2% to Rs 6.85 crore in Q3 FY24 as against with Rs 3.29 crore posted in Q3 FY23. While net sales stood at Rs 143.42 crore in Q3 FY24, registering a growth of 22.7% year on year.

The scrip shed 0.69% to end at Rs 331.45 on the BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 11 2024 | 3:41 PM IST

Next Story